Breast cancer leads the way in ADC therapy
Lessons learned from the use of second-generation antibody–drug conjugates (ADCs) in breast cancer can direct treatment in other tumour types
Lessons learned from the use of second-generation antibody–drug conjugates (ADCs) in breast cancer can direct treatment in other tumour types
Recent evidence shows the potential of immunotherapy to change the treatment landscape of triple-negative breast cancer (TNBC), where historically, chemotherapy has been the only systemic option. But, how do we choose what therapy to give which patients?
Patient-reported data from the DESTINY-BREAST04 and TROPiCS-02 trials may help improve current knowledge of quality of life on long-term treatment
Numerically improved overall survival was shown with abemaciclib plus trastuzumab and fulvestrant in patients with advanced breast cancer
These results highlight the need to better investigate the mechanisms of action, define the optimal timing of administration and identify predictive biomarkers
Findings from the TROPiCS-02 trial show an overall survival benefit of sacituzumab govitecan in heavily pre-treated patients but raise questions about its optimal clinical implementation
An interim analysis of phase III data further supports the use of abemaciclib plus non-steroidal aromatase inhibitor in patients with HR+, HER2– advanced breast cancer
According to this year’s ESMO Women for Oncology awardee Prof. Fatima Cardoso, steps forward in gender equality have been made, but progress is still slow
Experience in breast cancer shows that treatment de-intensification must follow robust evidence, but also values and preferences to generate acceptance
A translational analysis of the DAISY trial improves knowledge on the mechanisms of action of the antibody–drug conjugate
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.